• DOI:10.1007/s12032-013-0585-9
Corpus ID: 7145902

TL-118—anti-angiogenic treatment in pancreatic cancer: a case report

@article{Breuer2013TL118antiangiogenicTI,
  title={TL-118—anti-angiogenic treatment in pancreatic cancer: a case report},
  author={Shani Breuer and Ofra Maimon and L. Appelbaum and T. Peretz and A. Hubert},
  journal={Medical Oncology},
  year={2013},
  volume={30},
  pages={1-4}
}

Shani Breuer, Ofra Maimon, +2 authors A. Hubert

Published 2013

Medicine

Medical Oncology

Pancreatic cancer is one of the most aggressive malignant tumors. In recent years, little progress has been made in understanding and treatment of the disease. The two most commonly used chemotherapy drugs approved for the treatment of pancreatic cancer are gemcitabine and fluorouracil. Anti-angiogenic treatment is one of the current promising approaches in cancer translational research. Its aim is to inhibit development of new blood vessels and thereby prevent further tumor growth. We present… CONTINUE READING

View on Springer

tiltanpharma.com

Save to Library

Create Alert

Cite

Launch Research Feed